Upstream Bio (UPB) Income from Continuing Operations (2023 - 2026)
Upstream Bio (UPB) recorded quarterly Income from Continuing Operations of 40561000.0 in Q1 2026, up 4.59% quarter-over-quarter from 42513000.0 in Q4 2025, and down 48.74% on a YoY basis from 79125722.15 in Q1 2025.
Upstream Bio (UPB) Income from Continuing Operations (2023 - 2026) Analysis & Trends
Upstream Bio's Income from Continuing Operations history runs 4 years deep, the most recent figure standing at 40561000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 48.74% year-over-year to 40561000.0; the TTM figure through Mar 2026 stood at 156719000.0 (down 97.97% YoY), while the FY2025 annual figure was 143428000.0, down 118.5% from the prior year.
- Income from Continuing Operations was 40561000.0 for Q1 2026 at Upstream Bio, up from 42513000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 7859000.0 in Q3 2023 to a low of 42513000.0 in Q4 2025.
- Historically, Income from Continuing Operations has averaged 24572727.27 across 4 years, with a median of 21242000.0 in 2024.
- The sharpest annual moves came in 2025 and 2026: Income from Continuing Operations sank 172.22% in 2025, then sank 48.74% in 2026.
- A 4-year view of Income from Continuing Operations shows it stood at 12811000.0 in 2023, then tumbled by 65.81% to 21242000.0 in 2024, then tumbled by 100.14% to 42513000.0 in 2025, then grew by 4.59% to 40561000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 40561000.0 (Q1 2026), 42513000.0 (Q4 2025), and 33729000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Upstream Bio | 339.03 Mn | 339.03 Mn | -3.94 Mn | -40.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -40.56 Mn |
| Dec 31, 2025 | -42.51 Mn |
| Sep 30, 2025 | -33.73 Mn |
| Jun 30, 2025 | -39.92 Mn |
| Mar 31, 2025 | -27.27 Mn |
| Dec 31, 2024 | -21.24 Mn |
| Sep 30, 2024 | -15.99 Mn |
| Jun 30, 2024 | -14.66 Mn |
| Mar 31, 2024 | -13.75 Mn |
| Dec 31, 2023 | -12.81 Mn |
| Sep 30, 2023 | -7.86 Mn |